Loading…
Avalyn Pharma Inc. is projected to decline to $26.17 by 2027, a -2% move from its current price of $26.82.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $25.97 | $26.82 | $27.69 | -0.01% |
| May 30 | $25.63 | $26.81 | $28.05 | -0.03% |
| May 31 | $25.37 | $26.81 | $28.33 | -0.04% |
| Jun 1 | $25.15 | $26.81 | $28.57 | -0.05% |
| Jun 2 | $24.96 | $26.80 | $28.78 | -0.06% |
| Jun 3 | $24.79 | $26.80 | $28.98 | -0.08% |
| Jun 4 | $24.63 | $26.80 | $29.15 | -0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.63 | $26.80 | $29.15 | -0.09% |
| Week 2 | $23.76 | $26.77 | $30.16 | -0.18% |
| Week 3 | $23.11 | $26.75 | $30.96 | -0.27% |
| Week 4 | $22.57 | $26.72 | $31.63 | -0.36% |
| Week 5 | $22.11 | $26.70 | $32.24 | -0.45% |
| Week 6 | $21.69 | $26.67 | $32.80 | -0.54% |
| Week 7 | $21.32 | $26.65 | $33.31 | -0.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis.
Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc.
and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
Avalyn Pharma Inc. AVLN is currently trading at $26.70 with a market cap of $1.18B. Its rank is 2428. The 2026 forecast shows min $26.63, avg $26.70, max $34.21 with ROI 0 and sentiment NEUTRAL.
Looking further out, the forecast envisions gradual growth: 2030 avg $28.43 with ROI 6.5, 2040 avg $41.16 with ROI 54.1, and 2050 avg $68.06 with ROI 154.9, on a bullish path in later years.
A major floor 0.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.7% away) — a key level to hold.
The nearest ceiling, 15.0% above — a clean break opens room to run.
A major ceiling 15.0% above — clearing it would confirm fresh momentum.
Key AVLN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.63 | $26.82 | $34.25 | 0% | Neutral | |
| $19.24 | $26.17 | $38.41 | -2% | Neutral | |
| $17.13 | $24.54 | $38.11 | -9% | Neutral | |
| $15.36 | $23.00 | $37.32 | -14% | Neutral | |
| $18.75 | $29.24 | $49.19 | +9% | Neutral | |
| $19.64 | $31.79 | $55.20 | +19% | Neutral | |
| $18.48 | $31.01 | $55.38 | +16% | Neutral | |
| $18.91 | $32.82 | $60.13 | +22% | Bullish | |
| $17.37 | $31.16 | $58.42 | +16% | Neutral | |
| $16.80 | $31.13 | $59.61 | +16% | Neutral | |
| $19.51 | $42.18 | $88.21 | +57% | Bullish | |
| $31.97 | $71.05 | $163.40 | +165% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $26.63 | $26.82 | $31.73 | +0.00% |
| June 2026 | $22.58 | $26.96 | $33.27 | +0.53% |
| July 2026 | $21.87 | $26.50 | $33.46 | -1.69% |
| August 2026 | $20.59 | $25.25 | $32.44 | -4.73% |
| September 2026 | $20.36 | $25.21 | $32.85 | -0.15% |
| October 2026 | $20.79 | $25.98 | $34.29 | +3.05% |
| November 2026 | $20.44 | $25.75 | $34.35 | -0.92% |
| December 2026 | $20.01 | $25.41 | $34.25 | -1.31% |
Click any year to see its month-by-month AVLN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Avalyn Pharma Inc.'s 2026 outlook centres on $26.82, within a $26.63 to $34.25 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, AVLN could reach as high as $38.41, with a base case around $26.17 and support toward $19.24 — roughly -2% from $26.82. A consolidation phase looks the most probable path here.
Expect AVLN to range from $17.13 to $38.11 through 2028. The $24.54 average target implies a -9% move from current prices. That is -6% versus the projected 2027 average. Price action looks broadly range-bound.
The AVLN price prediction for 2029 points to an average of $23.00 (low $15.36, high $37.32) — a potential decline of -14% on today's $26.82. A consolidation phase looks the most probable path here.
In 2030, AVLN is projected to trade between $18.75 and $49.19, averaging $29.24 — a potential gain of +9% from today's $26.82. That is up +27% on the projected 2029 average. Price action looks broadly range-bound.
Avalyn Pharma Inc.'s 2031 outlook centres on $31.79, within a $19.64 to $55.20 range. That is up +9% on the projected 2030 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, AVLN could reach as high as $55.38, with a base case around $31.01 and support toward $18.48 — roughly +16% from $26.82. Price action looks broadly range-bound.
Expect AVLN to range from $18.91 to $60.13 through 2033. The $32.82 average target implies a +22% move from current prices. That is up +6% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The AVLN price prediction for 2034 points to an average of $31.16 (low $17.37, high $58.42) — a potential gain of +16% on today's $26.82. Price action looks broadly range-bound.
In 2035, AVLN is projected to trade between $16.80 and $59.61, averaging $31.13 — a potential gain of +16% from today's $26.82. That is 0% versus the projected 2034 average. A consolidation phase looks the most probable path here.
Avalyn Pharma Inc.'s 2040 outlook centres on $42.18, within a $19.51 to $88.21 range. That is up +36% on the projected 2035 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2050, AVLN could reach as high as $163.40, with a base case around $71.05 and support toward $31.97 — roughly +165% from $26.82. Buyers look set to stay in control over this stretch.
Investing $1,000 in AVLN today (≈ 37.285608 AVLN) could be worth
$2,648.96
+$1,648.96 (+165%) by 2050 · US Dollar
Based on the average projected AVLN price of $71.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AVLNwould be worth at today's price.
$1,000 invested in AVLN on Apr 30, 2026 (≈ 33.9098 AVLN) would be worth
$909.46
-$90.54 (-9.1%) today · 0.91× · US Dollar
Based on a AVLN entry price of $29.49 vs. today's $26.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $28.03 | $956.83 | -4.3% |
| All time ago | $29.49 | $909.46 | -9.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AVLN forecast.
Our base-case forecast reaches $54.00 around 2050.
Implied market cap at $54.00: $2.39B
In the multi-year forecast, the average price rises from $28.43 in 2030 with ROI 6.5. By 2033 the forecast shows average momentum with avg $32.34 and max $59.92 and ROI 21.1, signaling bullish sentiment. The 2040 forecast shows avg $41.16 with ROI 54.1 and a BULLISH sentiment, and the 2050 forecast shows avg $68.06 with ROI 154.9 and a BULLISH sentiment.
Early years display negative momentum (2027 ROI -2.7, 2028 -9.4, 2029 -16) before the later upturn. These are estimates and not guarantees, and actual results may vary.
Tap a question to reveal the answer.
Avg $28.43; min $18.03; max $48.31; ROI 6.5; sentiment NEUTRAL.
Forecast shows a mix of signals: negative ROI in 2027 (-2.7), 2028 (-9.4), and 2029 (-16), with positive momentum returning in later years (2030+; 2040; 2050). These are estimates and not a guarantee.
The forecast max is $59.92 in 2033, which is just under $60.
Avg $41.16; max $87.27; min $18.52; ROI 54.1; sentiment BULLISH.
Current price $26.70; market cap $1.18B.
Avalyn Pharma Inc. Community Discussion
0Share your Avalyn Pharma Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.